Health1 min read

Halozyme wins court order to block Merck's injected Keytruda in select European markets - Reuters

By · Published by Everything Blog

In short

Halozyme has won a court order blocking Merck's injected version of Keytruda from being sold in certain European markets, aiming to ensure fair competition and protect patients from higher costs.

Key points

  • Halozyme's drug, Kynamar, is approved for use in European markets where Merck's injected…: Halozyme's drug, Kynamar, is approved for use in European markets where Merck's injected version is not.
  • The court order prevents Merck's injected version from being sold, ensuring fair competit…: The court order prevents Merck's injected version from being sold, ensuring fair competition.
  • This ruling aims to maintain market integrity and protect patients from potentially highe…: This ruling aims to maintain market integrity and protect patients from potentially higher costs.

Halozyme wins court order to block Merck's injected Keytruda in select European markets    Reuters

Original source: news.google.com

Health